Gerald delivers as promised Lympro "new data" and it is looking good. moving into RUO in 4th quarter! As we have reviewed earlier, the RUO market is significant in and of itself. We are underway, and preparing to launch Eltoprazine into Phase 2b, and MANF multi IND applications with FDA. What an opportunity to add at this level. Well done Gerald, let's do it!!